Trial Protocol ID USOR 22198_FURMO-004 *STAR*

Trial Description

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Contact us regarding Clinical Trials at or call us at 877-664-7724

Disease Types


  • ArriVent BioPharma, Inc. NCT ID

  • NCT05607550